TXG · XBRL financial data

10x Genomics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (TXG's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	299	490	516	619	611	643
Cost of revenue	58	74	120	209	196	199
Gross profit	240	416	396	409	414	444
Selling, general and administrative	202	258	298	343	344	316
Total operating expenses	775	469	564	675	609	505
Operating income (loss)	(534)	(52)	(168)	(265)	(195)	(61)
Interest income	2	0	7	17	18	20
Interest expense	2	1	0	0	0	0
Other income (expense)	1	(1)	(0)	(0)	(2)	1
Income tax expense (benefit)	8	5	4	6	5	4
Net income (loss)	(543)	(58)	(166)	(255)	(183)	(44)
Earnings per share, basic USD per share	(5.37)	(0.53)	(1.46)	(2.18)	(1.52)	(0.35)
Earnings per share, diluted USD per share	(5.37)	(0.53)	(1.46)	(2.18)	(1.52)	(0.35)
Weighted average shares, basic millions of shares	101	110	114	117	120	125
Weighted average shares, diluted millions of shares	101	110	114	117	120	125

Fiscal years (TXG's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	664	587	220	359	344	474
Marketable securities	—	0	210	29	49	49
Accounts receivable	51	85	104	115	88	47
Inventory	30	60	82	74	83	56
Prepaid and other current assets	13	14	17	19	20	22
Total current assets	774	748	635	596	584	684
Property and equipment, net	73	169	289	280	253	227
Right-of-use asset	47	61	70	65	57	60
Goodwill	0	5	5	5	5	5
Total assets	929	1,019	1,029	965	919	1,041
Accounts payable	5	17	22	16	13	13
Current portion of long-term debt	0	—	—	—	—	—
Total current liabilities	118	110	131	127	118	153
Long-term debt	0	—	—	—	—	—
Lease liability, non-current	57	77	86	84	73	73
Total liabilities	190	201	223	224	209	245
Accumulated deficit	(805)	(863)	(1,029)	(1,284)	(1,467)	(1,511)
Total stockholders' equity	739	818	806	741	710	796
Total liabilities and equity	929	1,019	1,029	965	919	1,041
Common shares outstanding (cover page) millions of shares	108	113	115	119	122	128

Fiscal years (TXG's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(543)	(58)	(166)	(255)	(183)	(44)
Stock-based compensation	49	96	137	167	141	109
Depreciation and amortization	14	21	25	36	36	36
Net cash from operating activities	(218)	(21)	(34)	(15)	7	136
Purchases of property and equipment	37	101	132	49	12	6
Net cash from investing activities	(38)	(107)	(351)	133	(33)	(13)
Proceeds from issuing common stock	482	0	0	—	—	—
Proceeds from long-term debt	0	—	—	—	—	—
Repayments of long-term debt	31	0	0	—	—	—
Net cash from financing activities	469	35	16	14	11	7
Net change in cash	212	(93)	(369)	132	(15)	130

SIC 3826 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3826 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
10x Genomics	503	151	17*	not reported	—	Q2 FY26 10-QJun 30, 2026
Cohu	272	173	5.6*	47.3M	—	Q3 FY26 10-QSep 26, 2026
Aehr Test Systems	116	19*	1.8*	32.6M	—	Q4 FY26 10-KMay 29, 2026
Transcat	5.8	97	10*	9.4M	—	Q2 FY27 10-QSep 26, 2026
EyePoint	110	0.5	(62)*	86.2M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Onto Innovation	1,253	343	62*	49.1M	—	Q2 FY26 10-QJun 30, 2026
Ralliant	271	568	106*	110.6M	—	Q2 FY26 10-QJul 3, 2026
Allient	42	154	14*	17.0M	—	Q2 FY26 10-QJun 30, 2026
Crawford United	1.9	not reported	5.7*	not reported	—	Q3 FY25 10-QSep 30, 2025

Not investment advice. Not affiliated with the U.S. SEC.